CommentActual costs of cancer drugs in 15 European countries
References (8)
- et al.
Delivering affordable cancer care in high-income countries
Lancet Oncol
(2011) - et al.
Economic burden of cancer across the European Union: a population-based cost analysis
Lancet Oncol
(2013) - et al.
A standardized generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for medical oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)
Ann Oncol
(2015) - et al.
Cancer Core Europe: a first step towards a virtual cancer institute in Europe?
Mol Oncol
(2014)
There are more references available in the full text version of this article.
Cited by (0)
Copyright © 2016 Elsevier Ltd. All rights reserved.